sclcM1141057A2_S62.txt
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.390
- PANCREAS_BETA_CELLS+0.350
- MITOTIC_SPINDLE+0.320
- G2M_CHECKPOINT+0.300
- P53_PATHWAY+0.210
- INTERFERON_ALPHA_RESPONSE+0.200
- TGF_BETA_SIGNALING+0.200
- UV_RESPONSE_UP+0.140
- APICAL_JUNCTION+0.120
- ESTROGEN_RESPONSE_EARLY+0.110
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- ALLOGRAFT_REJECTION-0.330
- INFLAMMATORY_RESPONSE-0.300
- MTORC1_SIGNALING-0.300
- ANGIOGENESIS-0.280
- COAGULATION-0.270
- XENOBIOTIC_METABOLISM-0.270
- COMPLEMENT-0.260
- IL6_JAK_STAT3_SIGNALING-0.240
- GLYCOLYSIS-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-4741-01A-01R-1436-07 | — | — | 0.692 |
| 2 | MBCProject_1542_T1_RNA | — | B | 0.676 |
| 3 | SRR13780248 | — | cohortSC | 0.676 |
| 4 | TCGA-GV-A3QH-01A-11R-A220-07 | — | — | 0.667 |
| 5 | SRR8613731 | — | E | 0.667 |
| 6 | SRR975552 | — | — | 0.660 |
| 7 | TCGA-52-7809-01A-21R-2125-07 | — | cohortMD1 | 0.658 |
| 8 | SRR8752373 | — | — | 0.655 |
| 9 | TCGA-75-6214-01A-41R-1949-07 | — | cohortSQ1 | 0.654 |
| 10 | SRR6013553 | — | cohortA3 | 0.652 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.010 | Idelalisib | — uncovered |
| PEROXISOME | 0.010 | Idelalisib | — uncovered |